Gero has raised an additional $17 million in funding, bringing the company’s total capital raised to $34 million.
The biotech startup uses artificial intelligence and physics-based models to study aging and develop potential therapies targeting age-related diseases and longevity.
The new funding will support preclinical research programs and help expand partnerships with major pharmaceutical companies.
AI Meets Longevity Research
Gero is part of a growing group of biotechnology companies applying artificial intelligence to drug discovery and aging research.
The company seeks to identify biological mechanisms associated with aging and use computational models to accelerate the development of new medicines.
Supporters of the approach believe AI can significantly reduce the time and cost required to discover promising drug candidates.
The latest financing reflects continued investor interest in both AI-powered healthcare technologies and the rapidly expanding longevity sector.
Funding Targets Drug Development
The fresh capital will primarily be used to advance preclinical programs and strengthen collaborations with pharmaceutical partners.
Biotechnology companies focused on aging have attracted increasing attention in recent years as advances in AI, genomics, and computational biology create new opportunities for research.
Investors view aging as one of the largest unmet medical challenges, with potential applications spanning multiple chronic diseases.
The broader takeaway is that Gero is continuing to attract investor support for its AI-driven approach to longevity research, positioning itself at the intersection of artificial intelligence, biotechnology, and drug discovery.
